Table 2.
FGFR aberrations by tumor type in patients receiving futibatinib 20 mg once daily
| Tumor type | Gene | Fusions/rearrangements, n (%) | Mutation, n (%) | Amplification, n (%) |
|---|---|---|---|---|
| Cholangiocarcinoma (n = 64)a | FGFR1 | 1 (1.6) | 0 | 0 |
| FGFR2 | 43 (67.2) | 13 (20.3) | 0 | |
| FGFR3 | 1 (1.6) | 0 | 0 | |
| FGF1 | 0 | 0 | 7 (10.9) | |
| FGF3 | 0 | 0 | 6 (9.4) | |
| FGF4 | 0 | 0 | 5 (7.8) | |
| FGF19 | 0 | 0 | 8 (12.5) | |
| Primary CNS (n = 36) | FGFR1 | 2 (5.6) | 9 (25.0) | 0 |
| FGFR2 | 0 | 1 (2.8) | 0 | |
| FGFR3 | 23 (63.9) | 1 (2.8) | 1 (2.8) | |
| Urothelial cancer (n = 19) | FGFR1 | 0 | 1 (5.3) | 1 (5.3) |
| FGFR3 | 3 (15.8) | 13 (68.4) | 0 | |
| FGF1 | 0 | 0 | 4 (21.1) | |
| FGF3 | 0 | 0 | 4 (21.1) | |
| FGF4 | 0 | 0 | 2 (10.5) | |
| FGF19 | 0 | 0 | 4 (21.1) | |
| Breast (n = 11) | FGFR1 | 0 | 0 | 1 (9.1) |
| FGFR2 | 2 (18.2) | 1 (9.1) | 5 (45.5) | |
| FGFR3 | 0 | 0 | 1 (9.1) | |
| FGFR4 | 0 | 1 (9.1) | 0 | |
| FGF1 | 0 | 0 | 5 (45.5) | |
| FGF3 | 0 | 0 | 4 (36.4) | |
| FGF4 | 0 | 0 | 3 (27.3) | |
| FGF19 | 0 | 0 | 5 (45.5) | |
| Gastric (n = 9) | FGFR2 | 1 (11.1) | 0 | 8 (88.9) |
| FGFR3 | 1 (11.1) | 0 | 0 | |
| FGF1 | 0 | 0 | 2 (22.2) | |
| FGF3 | 0 | 0 | 2 (22.2) | |
| FGF4 | 0 | 0 | 1 (11.1) | |
| FGF19 | 0 | 0 | 2 (22.2) | |
| Other (n = 31) | FGFR1 | 2 (6.5) | 0 | 0 |
| FGFR2 | 2 (6.5) | 8 (25.8) | 8 (25.8) | |
| FGFR3 | 4 (12.9) | 1 (3.2) | 1 (3.2) | |
| FGFR4 | 0 | 2 (6.5) | 0 | |
| FGF1 | 0 | 0 | 3 (9.7) | |
| FGF3 | 0 | 0 | 2 (6.5) | |
| FGF4 | 0 | 0 | 1 (3.2) | |
| FGF19 | 0 | 0 | 3 (9.7) |
aSixty-one patients had intrahepatic CCA, and 3 patients had extrahepatic CCA harboring FGFR2 fusions/rearrangements (n = 1), FGF19 amplification (n = 1), and FGFR2 mutation (n = 1).